End-of-day quote
Shanghai S.E.
03:30:00 10/05/2024 am IST
|
5-day change
|
1st Jan Change
|
4.12
CNY
|
-2.37%
|
|
+0.24%
|
-27.85%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
4,143
|
6,635
|
5,361
|
4,737
|
3,886
|
3,879
|
Enterprise Value (EV)
1 |
4,198
|
6,725
|
5,467
|
4,932
|
4,093
|
4,090
|
P/E ratio
|
97.6
x
|
120
x
|
-95.5
x
|
-45
x
|
-1,078
x
|
634
x
|
Yield
|
0.41%
|
0.28%
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
4.11
x
|
4.74
x
|
5.7
x
|
4.55
x
|
4.93
x
|
5.71
x
|
EV / Revenue
|
4.16
x
|
4.8
x
|
5.81
x
|
4.74
x
|
5.19
x
|
6.02
x
|
EV / EBITDA
|
60.7
x
|
63.6
x
|
63
x
|
48.9
x
|
123
x
|
94.1
x
|
EV / FCF
|
87.2
x
|
-192
x
|
185
x
|
132
x
|
-179
x
|
26.1
x
|
FCF Yield
|
1.15%
|
-0.52%
|
0.54%
|
0.76%
|
-0.56%
|
3.83%
|
Price to Book
|
3.61
x
|
5.61
x
|
4.86
x
|
5.17
x
|
4.4
x
|
4.22
x
|
Nbr of stocks (in thousands)
|
6,84,712
|
6,84,712
|
6,84,712
|
6,83,512
|
6,79,347
|
6,79,347
|
Reference price
2 |
6.050
|
9.690
|
7.830
|
6.930
|
5.720
|
5.710
|
Announcement Date
|
19/04/19
|
24/04/20
|
29/04/21
|
29/04/22
|
28/04/23
|
29/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,008
|
1,400
|
940.3
|
1,041
|
789
|
679.7
|
EBITDA
1 |
69.2
|
105.7
|
86.75
|
100.9
|
33.17
|
43.49
|
EBIT
1 |
44.46
|
81.26
|
62.38
|
75.91
|
8.631
|
3.406
|
Operating Margin
|
4.41%
|
5.8%
|
6.63%
|
7.29%
|
1.09%
|
0.5%
|
Earnings before Tax (EBT)
1 |
65.22
|
84.08
|
-36.44
|
-66.63
|
3.922
|
23.48
|
Net income
1 |
42.79
|
55.51
|
-55.83
|
-105.4
|
-3.61
|
5.963
|
Net margin
|
4.24%
|
3.97%
|
-5.94%
|
-10.12%
|
-0.46%
|
0.88%
|
EPS
2 |
0.0620
|
0.0810
|
-0.0820
|
-0.1540
|
-0.005306
|
0.009000
|
Free Cash Flow
1 |
48.14
|
-35.1
|
29.51
|
37.48
|
-22.85
|
156.6
|
FCF margin
|
4.77%
|
-2.51%
|
3.14%
|
3.6%
|
-2.9%
|
23.04%
|
FCF Conversion (EBITDA)
|
69.57%
|
-
|
34.02%
|
37.15%
|
-
|
360.1%
|
FCF Conversion (Net income)
|
112.51%
|
-
|
-
|
-
|
-
|
2,626.09%
|
Dividend per Share
2 |
0.0250
|
0.0270
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/04/19
|
24/04/20
|
29/04/21
|
29/04/22
|
28/04/23
|
29/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
55.7
|
90.5
|
106
|
195
|
207
|
211
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.8044
x
|
0.8557
x
|
1.224
x
|
1.935
x
|
6.236
x
|
4.856
x
|
Free Cash Flow
1 |
48.1
|
-35.1
|
29.5
|
37.5
|
-22.8
|
157
|
ROE (net income / shareholders' equity)
|
4.1%
|
4.92%
|
-4.17%
|
-9.55%
|
0.07%
|
0.74%
|
ROA (Net income/ Total Assets)
|
1.11%
|
2.13%
|
1.85%
|
2.37%
|
0.29%
|
0.12%
|
Assets
1 |
3,850
|
2,608
|
-3,022
|
-4,453
|
-1,264
|
5,127
|
Book Value Per Share
2 |
1.680
|
1.730
|
1.610
|
1.340
|
1.300
|
1.350
|
Cash Flow per Share
2 |
0.5200
|
0.4300
|
0.4500
|
0.4500
|
0.4600
|
0.5100
|
Capex
1 |
15.8
|
13.2
|
19.6
|
26.9
|
20.9
|
7.51
|
Capex / Sales
|
1.57%
|
0.94%
|
2.08%
|
2.59%
|
2.65%
|
1.1%
|
Announcement Date
|
19/04/19
|
24/04/20
|
29/04/21
|
29/04/22
|
28/04/23
|
29/04/24
|
|
1st Jan change
|
Capi.
|
---|
| -27.85% | 387M | | +19.62% | 43.27B | | +24.52% | 22.92B | | +20.29% | 15.43B | | +7.48% | 12.95B | | +42.51% | 11.83B | | -8.84% | 6.91B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +13.13% | 5.55B |
Generic Pharmaceuticals
|